Evidence map›Paper›PMID 34744426›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2021

Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis.

Nicola L Harman, Sarah L Gorst, Paula R Williamson, Elliot S Barnathan, Robert P Baughman, Marc A Judson, Heidi Junk, Nynke A Kampstra, Eugene J Sullivan, David E Victorson and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. D. Geraint James Lecture: The sarcoidosis saga: what insights from the past will guide us in the future.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023
    Article
  4. Pulmonary Sarcoidosis: Beyond Restriction and Forced Vital Capacity.Annals of the American Thoracic Society · 2023
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nicola L HarmanDepartment of Health Data Science, University of Liverpool, Liverpool, UK.
Sarah L GorstDepartment of Health Data Science, University of Liverpool, Liverpool, UK.
Paula R WilliamsonDepartment of Health Data Science, University of Liverpool, Liverpool, UK.
Elliot S BarnathanJanssen Research and Development, LLC.
Robert P BaughmanDepartment of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA.
Marc A JudsonDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York, USA.
Heidi JunkPatient Advocate - Foundation for Sarcoidosis Research.
Nynke A KampstraDept of Value-Based Healthcare, St Antonius Hospital, Nieuwegein, The Netherlands.
Eugene J SullivanRadboud University Medical Center, Radboud Institute for Health Sciences, Scientific Center for Quality of Healthcare (IQ Healthcare), Nijmegen, The Netherlands.
David E VictorsonInsmed, Incorporated, Bridgewater, NJ, USA.
Marc WaltonNorthwestern University Feinberg School of Medicine, Evanston, IL, USA.
Tamara Al-HakimJanssen Research and Development, Titusville, NJ, USA.
Hana NabulsiJanssen Research and Development, Titusville, NJ, USA.
Noopur SinghJanssen Research and Development, Titusville, NJ, USA.
Jan C GruttersThe Foundation for Sarcoidosis Research, Chicago, Illinois, USA.
Daniel A CulverDivision of Heart & Lungs, University Medical Center Utrecht, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical trials evaluating different management strategies for pulmonary sarcoidosis may measure different outcomes. This heterogeneity in outcomes can lead to waste in research due to the inability to compare and combine data. Core outcome sets (COS) have the potential to address this issue and here we describe a systematic review of outcomes as the first step in the development of a COS for pulmonary sarcoidosis research.

methodsA search of clinical trial registries for phase II, III and IV trials of pulmonary sarcoidosis was undertaken along with a rapid review of the patient perspective literature. Each study was screened for eligibility and outcomes extracted verbatim from the registry entry or publication then reviewed, grouped and categorised using the COMET taxonomy.

results36 trial registry entries and 6 studies on patients' perspective of pulmonary sarcoidosis were included reporting 56 and 82 unique outcomes respectively across 23 domains. The most frequently reported outcome domain was "respiratory, thoracic and mediastinal outcomes". However, the patients' perspective literature identified outcomes in the "personal circumstances" and "societal/carer burden" domains that were not reported in any of the included trial registrations.

conclusionsUsing both clinical trial registry data and published literature on patients' perspective has allowed rapid review of outcomes measured and reported in pulmonary sarcoidosis research. The use of multiple sources has led to the development of a comprehensive list of outcomes that represents the first step in the development of a COS for use in future pulmonary sarcoidosis research.

Indexed as

Core outcome setOutcomesPulmonary sarcoidosisSystematic review

Identifiers

PMID34744426
PMCPMC8552570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.